V-007
O-Desmethylvenlafaxine solution
100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C16H25NO2
CAS Number:
Molecular Weight:
263.38
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
100 μg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
SMILES string
OC1=CC=C(C(CN(C)C)C2(O)CCCCC2)C=C1
InChI
1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
InChI key
KYYIDSXMWOZKMP-UHFFFAOYSA-N
Gene Information
human ... SLC6A2(6530) , SLC6A4(6532)
Looking for similar products? Visit Product Comparison Guide
General description
An analytical reference standard applicable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications such as urine drug testing, forensic analysis, or clinical toxicology. Also known as desvenlafaxine, O-desmethylvenlafaxine is an SNRI antidepressant marketed under the trade name Pristiq® for the treatment of depression. O-desmethylvenlafaxine is also a major urinary metabolite of venlafaxine, an SNRI antidepressant sold as Effexor® or Efexor and used to treat major depressive disorder, generalized anxiety disorder, and other anxiety disorders associated with depression.
Application
- Drug Stability in Pharmaceutical Formulations: Another study focused on the physical stability and solubility of O-Desmethylvenlafaxine in various pharmaceutical formulations, contributing to better drug delivery systems and enhanced therapeutic efficacy (Wang et al., 2020).
- Monitoring Drug Precursors in Advanced Treatment Processes: Research monitored N-nitrosodimethylamine (NDMA) precursors throughout membrane-based advanced wastewater treatment processes, considering the behavior of compounds like O-Desmethylvenlafaxine. This study aids in improving wastewater treatment strategies to mitigate pharmaceutical pollutants (Roccaro et al., 2020).
- Chiral Drug Analysis in Environmental Waters: A study developed a dual enantioselective LC-MS/MS method for analyzing chiral drugs in surface water, including O-Desmethylvenlafaxine. This method helps in understanding the environmental fate and behavior of chiral pharmaceuticals, enhancing environmental risk assessments (Coelho et al., 2019).
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Effexor is a registered trademark of American Home Product Corp.
Pristiq is a registered trademark of Wyeth LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
related product
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Target Organs
Eyes
Storage Class Code
3 - Flammable liquids
WGK
WGK 1
Flash Point(F)
49.5 °F - closed cup
Flash Point(C)
9.7 °C - closed cup
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Anita H Clayton et al.
The journal of sexual medicine, 10(3), 768-776 (2012-08-22)
The symptoms of major depressive disorder (MDD) include sexual dysfunction, but antidepressant pharmacotherapies are also associated with treatment-emergent sexual dysfunction. These secondary and post hoc analyses evaluated sexual functioning in employed adult outpatients with MDD treated with desvenlafaxine (administered as
JoAnn V Pinkerton et al.
Menopause (New York, N.Y.), 20(1), 38-46 (2012-12-26)
The purpose of this study was to assess the 1-year maintenance of the efficacy of desvenlafaxine 100 mg/day (administered as desvenlafaxine succinate) established on week 12 in a 1-year, double-blind, randomized, placebo-controlled trial in postmenopausal women seeking treatment of bothersome
G Gasser et al.
Chemosphere, 88(1), 98-105 (2012-03-27)
The stereoselectivity of R,S-venlafaxine and its metabolites R,S-O-desmethylvenlafaxine, N-desmethylvenlafaxine, O,N-didesmethylvenlafaxine, N,N-didesmethylvenlafaxine and tridesmethylvenlafaxine was studied in three processes: (i) anaerobic and aerobic laboratory scale tests; (ii) six wastewater treatment plants (WWTPs) operating under different conditions; and (iii) a variety of
R J Cheng et al.
Climacteric : the journal of the International Menopause Society, 16(1), 17-27 (2012-06-01)
To assess effects of desvenlafaxine (administered as desvenlafaxine succinate) on secondary outcomes of mood, climacteric symptoms, and treatment satisfaction in postmenopausal women with moderate to severe menopausal vasomotor symptoms (VMS). A 12-week, multicenter, double-blind, placebo-controlled trial was conducted in postmenopausal
Nakao Iwata et al.
Journal of psychiatric practice, 19(1), 5-14 (2013-01-22)
This study evaluated the efficacy and safety of low-dose desvenlafaxine (administered as desvenlafaxine succinate) in treating major depressive disorder (MDD). Adult outpatients (aged 18 years) in the United States and (aged 20 years) in Japan, who met Diagnostic and Statistical
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service